| Filed On | Filing |
|---|---|
| 14 Apr 2025 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
Expiration Date: Twenty-one (21) days following the Company’s public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Rena... |
Loading...
